文献速递分子诊断临床微生物

生殖支原体大环内酯耐药检测的自动化ASR实时RT-PCR优化与临床评估

Optimization and Clinical Evaluation of an Automated Commercial Analyte-Specific Reagent Assay for Mycoplasmoides genitalium Macrolide Resistance Detection in Primary Clinical Specimens.
PubMed 文献 · J Clin Microbiol · 2023-06-21

本研究优化了一种开放平台上的生殖支原体大环内酯耐药实时逆转录PCR试剂(ASR),并评估其在临床样本中检测23S rRNA耐药突变(MRM)的性能。优化后检测A2058G突变的下限为5000 copies/mL,临床标本MRM总检出率为67.3%(583/866),特异性100%,与Sanger测序一致率90.9%。

要点

  • 优化引物/探针及MgCl2浓度可减少野生型23S rRNA假阳性,提高MRM检出。
  • A2058G突变检测下限为5000 copies/mL(180 copies/反应,20/20检出)。
  • 临床标本MRM检出率67.3%,特异性100%,与Sanger测序一致率90.9%。

核心结论

  • 优化后的ASR实时RT-PCR可检测生殖支原体23S rRNA大环内酯耐药突变,临床性能良好。

研究设计与样本

  • 在开放平台上建立ASR实时逆转录PCR,优化参数后评估临床标本中MRM检测。
  • 临床标本包括生殖支原体商业转录介导扩增阳性样本866例。

主要发现

  • 初始引物/探针浓度下,10000 copies野生型RNA出现80%假阳性。
  • 优化后A2058G检测下限5000 copies/mL(180 copies/反应,20/20检出)。
  • 基线校正斜率限250单位可减少野生型23S rRNA假阳性至3.3 billion copies/mL挑战。
  • MRM总检出583/866(67.3%);拭子392/564(69.5%),首段尿191/302(63.2%),P=0.06。
  • ASR特异性100%(141份泌尿生殖标本),与Sanger测序一致率90.9%。

关键数值与推荐

  • A2058G突变检测下限:5000 copies/mL(180 copies/反应,20/20检出)。
  • MRM检出率:总67.3%(583/866),拭子69.5%(392/564),首段尿63.2%(191/302),P=0.06。
  • 性别间耐药检出率无差异(P=0.76),特异性100%(141份)。

临床怎么用

  • 该ASR检测可用于生殖支原体阳性患者的大环内酯耐药突变检测,指导用药。
  • 需注意优化引物/探针及MgCl2浓度以减少野生型假阳性,并设置基线校正斜率限。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With improvement in laboratory diagnosis of Mycoplasmoides genitalium infection through molecular diagnostics, macrolide resistance determination within M. genitalium-positive patients is necessary. In this study, we report baseline parameters for an analyte-specific reagent (ASR) macrolide resistance real-time reverse transcriptase PCR on an open access analyzer and evaluated detection of macrolide resistance-mediated mutation (MRM) within 23S rRNA in a clinical specimen set. Initial use of 1.2 μM M. genitalium primer and 0.8 μM M. genitalium detection probe concentrations yielded an 80% false-positive detection rate when challenged with 10,000 copies of wild-type RNA. Optimization experiments showed that lowering primer/detection probe and MgCl2 concentrations minimized these false-detections of wild-type 23S rRNA, while higher levels of KCl increased rates of MRM detection with concomitant lower cycle threshold values and higher fluorescence emission. Lower limit of A2058G mutation detection was 5000 copies/mL (180 copies/reaction; 20/20 detections). Utilization of a baseline correction slope limit of 250 units further mitigated false-detection from wild-type 23S rRNA at challenges up to 3.3 billion copies/mL. MRM was detected in 583/866 (67.3%) clinical specimens initially positive for M. genitalium by commercial transcription-mediated amplification. These data included 392/564 detections (69.5%) from M. genitalium-positive swab specimens and 191/302 (63.2%) from M. genitalium-positive-positive first-void urine specimens (P = 0.06). Overall resistance detection rates did not vary by gender (P = 0.76). Specificity of the M. genitalium macrolide resistance ASR was 100% (141 urogenital determinations). MRM detection by the ASR was confirmed at a concordance rate of 90.9% by Sanger sequencing of a clinical specimen subset.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Munson E, Zapp A, Moore J, et al. Optimization and Clinical Evaluation of an Automated Commercial Analyte-Specific Reagent Assay for Mycoplasmoides genitalium Macrolide Resistance Detection in Primary Clinical Specimens. J Clin Microbiol. 2023. PMID: 37341596. doi:10.1128/jcm.00335-23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。